<DOC>
	<DOCNO>NCT01622569</DOCNO>
	<brief_summary>The primary objective study compare efficacy intranasal administration 100 , 200 , 400 μg fluticasone propionate twice day deliver OptiNose device placebo subject bilateral nasal polyposis . Two co-primary endpoint use study : reduction nasal congestion/obstruction symptom end Week 4 double-blind treatment phase measure 7 day average instantaneous AM diary symptom score , reduction total polyp grade ( sum score nasal cavity ) 16 week double-blind treatment phase determine Lildholdt scale score measure nasoendoscopy .</brief_summary>
	<brief_title>Study Evaluating Efficacy Safety Intranasal Administration 100 , 200 , 400 μg Fluticasone Propionate Twice Day ( BID ) Using Novel Bi Directional Device Subjects With Bilateral Nasal Polyposis Followed 8-Week Open-Label Extension Phase Assess Safety</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Nasal Polyps</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Men woman age 18 year old Women must practice effective method birth control ( eg , prescription oral contraceptive , contraceptive injection , contraceptive patch , intrauterine device , doublebarrier method [ eg , condom , diaphragm , cervical cap spermicidal foam , cream , gel ] , male partner sterilization ) entry throughout study , surgically sterile ( hysterectomy bilateral oophorectomy , tubal ligation least 1 year screen ) otherwise incapable pregnancy , postmenopausal ( spontaneous amenorrhea least 1 year ) . Women childbearing potential must negative serum betahuman chorionic gonadotropin ( BhCG ) urine pregnancy test ( depend local regulation ) screen visit Must bilateral nasal polyposis grade 1 3 nasal cavity determine Lildholdt scale score measure nasoendoscopy screen baseline visit Must least moderate symptom nasal congestion/obstruction report subject 7 day period precede screen visit At baseline visit ( Day 1 ) , must morning score least 2 ( moderate ) nasal congestion/obstruction record subject diary least 5 last 7 day 7 14 day runin period Must demonstrate ability correctly complete daily diary runin period eligible randomization Subjects comorbid asthma COPD must stable exacerbation ( eg , emergency room visit , hospitalization , oral parenteral steroid use ) within 3 month screen visit . Inhaled corticosteroid use must limit stable dos 1,000 μg/day beclomethasone ( equivalent ) least 3 month screen plan continue use throughout study . Must able cease treatment intranasal medication include , limited , intranasal steroid , intranasal sodium cromolyn , nasal atropine , nasal ipratropium bromide , inhaled corticosteroid ( except permit dos list comorbid asthma COPD ) screen visit Must able cease treatment oral nasal decongestant antihistamine screen visit Must able use OptiNose device correctly ; subject require demonstrate correct use placebo device screening , Visit 1 . Must capable , opinion investigator , provide informed consent participate study . Subjects must sign informed consent document indicate understand purpose procedure require study willing participate study . Women pregnant lactating Have complete nearcomplete obstruction nasal cavity Inability achieve bilateral nasal airflow reason include nasal septum deviation Inability nasal cavity examine reason include nasal septum deviation Nasal septum perforation Has 1 episode epistaxis frank bleed month screen visit Have evidence significant baseline mucosal injury , ulceration erosion ( eg , exposed cartilage , perforation ) baseline nasal examination/nasal endoscopy History 5 sinonasal surgery either nasal polyp nasal/sinus inflammation ( lifetime ) History sinus nasal surgery within 6 month screen visit History surgical procedure prevents ability accurately grade polyp Have symptoms seasonal allergic rhinitis screen baseline and/or , base time year , would anticipate onset symptom within 4 week randomization Current , ongoing rhinitis medicamentosa ( rebound rhinitis ) Have significant oral structural abnormality , eg , cleft palate Diagnosis cystic fibrosis History ChurgStrauss syndrome dyskinetic ciliary syndrome Purulent nasal infection , acute sinusitis , upper respiratory tract infection within 2 week screen visit . Potential subject present infection may rescreened 4 week symptom resolution Note : Subjects take prophylactic antibiotic allow enter study long intend continue antibiotic duration study . Planned sinonasal surgery period study Allergy , hypersensitivity , contraindication corticosteroid steroid Allergy hypersensitivity excipients study drug Exposure glucocorticoid treatment potential systemic effect ( eg , oral , parenteral , intraarticular , epidural steroid , high dose topical steroid ) within 1 month screen visit ; except note inclusion criterion subject comorbid asthma COPD Have nasal candidiasis Have take potent CYP3A4 inhibitor within 14 day screen visit . History current diagnosis form glaucoma ocular hypertension ( ie , &gt; 21 mmHg ) History intraocular pressure elevation form steroid therapy History current diagnosis presence ( either eye ) cataract Any serious unstable concurrent disease , psychiatric disorder , significant condition , opinion investigator could confound result study could interfere subject 's participation compliance study A recent ( within 1 year screen visit ) clinically significant history drug alcohol use , abuse , dependence , opinion investigator could interfere subject 's participation compliance study Positive urine drug screen screen visit drug abuse , exception prescribe medication legitimate medical condition Have participate investigational drug clinical trial within 30 day screen visit Employees investigator study center , direct involvement propose study study direction investigator study center , well family member employee investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>